HT
CRSP icon

HAP Trading’s CRISPR Therapeutics CRSP Stock Holding History

HAP Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,400
Closed -$1.53K – 707
2024
Q1 		$1.53K Buy
+20,400
New +$1.46M ﹤0.01% 671
2023
Q3 		– Sell
-40,700
Closed -$194K – 1079
2023
Q2 		$194K Buy
+40,700
New +$2.31M 0.03% 310
2023
Q1 		– Sell
-20,200
Closed -$3K – 1271
2022
Q4 		$3K Sell
20,200
-1,500
-7% -$79.6K ﹤0.01% 1303
2022
Q3 		$42K Buy
21,700
+700
+3% +$50.7K ﹤0.01% 1028
2022
Q2 		$48K Buy
21,000
+2,400
+13% +$141K ﹤0.01% 1062
2022
Q1 		$47K Sell
18,600
-9,300
-33% -$584K ﹤0.01% 1279
2021
Q4 		$77K Buy
27,900
+5,700
+26% +$498K ﹤0.01% 1315
2021
Q3 		$159K Sell
22,200
-2,200
-9% -$276K 0.01% 1113
2021
Q2 		$620K Sell
24,400
-61,700
-72% -$7.5M 0.02% 588
2021
Q1 		$322K Buy
86,100
+57,300
+199% +$8.65M 0.02% 621
2020
Q4 		$1.46M Buy
28,800
+12,300
+75% +$1.45M 0.04% 331
2020
Q3 		$425K Buy
16,500
+5,500
+50% +$488K 0.02% 435
2020
Q2 		$330K Sell
11,000
-6,900
-39% -$403K 0.02% 547
2020
Q1 		$133K Sell
17,900
-7,000
-28% -$361K 0.01% 620
2019
Q4 		$354K Buy
24,900
+11,900
+92% +$650K 0.02% 369
2019
Q3 		$131K Sell
13,000
-2,200
-14% -$105K 0.01% 572
2019
Q2 		$103K Sell
15,200
-10,300
-40% -$412K 0.01% 600
2019
Q1 		$57K Buy
25,500
+9,800
+62% +$339K 0.01% 644
2018
Q4 		$19K Buy
+15,700
New +$546K ﹤0.01% 874

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

HAP Trading's CRSP Position: Q2 2022 in Review

HAP Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 10,951 shares — an estimated $644K sold.

HAP Trading first reported a position in CRSP in Q2 2020 and held it in 5 quarters. The position peaked at $1.62M in Q4 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • HAP Trading reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • HAP Trading sold 10,951 CRISPR Therapeutics shares in Q2 2022, an estimated $644K.
  • HAP Trading first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 5 quarters.
  • HAP Trading's CRISPR Therapeutics position peaked at $1.62M in Q4 2020.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on HAP Trading's 13F filing for Q2 2022, filed 12 Aug 2022.